ReviewTherapeutic advances in neurological disorders2019
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.
Review in Therapeutic advances in neurological disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Functional and effective EEG connectivity patterns in Alzheimer's disease and mild cognitive impairment: a systematic review.Frontiers in aging neuroscience · 2025Pooled it
- Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer's Disease: A Systematic Review and Meta-Analysis.Biomolecules · 2021Pooled it
- Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.Alzheimer's research & therapy · 2021Trial
- Blood-based multiplex nanobiosensing of Alzheimer's disease biomarkers: from nanoengineered ınterfaces to clinical translation.Metabolic brain disease · 2026Review
- Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.EBioMedicine · 2026Article
- Elevated circulating BACE2 captures chronic glycemic burden and enhances the clinical identification of type 2 diabetes.iScience · 2026Article
- 3D quantitative synthetic MRI for assessing Alzheimer's clinical syndrome, subjective cognitive impairment, and mild cognitive impairment.Neuroradiology · 2026Article
- Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.Biophysical reviews · 2026Review
- Associations of amyloid biomarkers with brain and cognitive changes from imaging, spinal fluid, and plasma.medRxiv : the preprint server for health sciences · 2026Article
- Interpretable machine learning model based on multimodal MRI radiomics for Alzheimer's disease diagnosis.Frontiers in aging neuroscience · 2026Article
- Lumbar puncture seems to be safe and practical ın oldest-old patients: a protocol from a memory center.European geriatric medicine · 2025Article
- A radiomics model predicts progression from mild cognitive impairment to alzheimer's disease using structural MRI.Scientific reports · 2025Article
- Harnessing brain-derived extracellular vesicles to support RDoC-based drug development.Neuroscience applied · 2025Review
- Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal Dementia.Biomedicines · 2024Article
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
- Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Germanium Dioxide Nanoparticles Mitigate Biochemical and Molecular Changes Characterizing Alzheimer's Disease in Rats.Pharmaceutics · 2023Article
- Impact of Nut Consumption on Cognition across the Lifespan.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease and its diagnosis has classically been based on clinical symptoms. Recently, a biological rather than a syndromic definition of the disease has been proposed that is based on biomarkers that reflect neuropathological changes. In AD, there are two main biomarker categories, namely neuroimaging and fluid biomarkers [cerebrospinal fluid (CSF) and blood]. As a complex and multifactorial disease, AD biomarkers are important for an accurate diagnosis and to stage the disease, assess the prognosis, test target engagement, and measure the response to treatment. In addition, biomarkers provide us with information that, even if it does not have a current clinical use, helps us to understand the mechanisms of the disease. In addition to the pathological hallmarks of AD, which include amyloid-β and tau deposition, there are multiple concomitant pathological events that play a key role in the disease. These include, but are not limited to, neurodegeneration, inflammation, vascular dysregulation or synaptic dysfunction. In addition, AD patients often have an accumulation of other proteins including α-synuclein and TDP-43, which may have a pathogenic effect on AD. In combination, there is a need to have biomarkers that reflect different aspects of AD pathogenesis and this will be important in the future to establish what are the most suitable applications for each of these AD-related biomarkers. It is unclear whether sex, gender, or both have an effect on the causes of AD. There may be differences in fluid biomarkers due to sex but this issue has often been neglected and warrants further research. In this review, we summarize the current state of the principal AD fluid biomarkers and discuss the effect of sex on these biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.